Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
Tracking Information | |||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Received Date ICMJE | May 29, 2008 | ||||||||||||||||||||||||||||||||
Last Updated Date | October 21, 2010 | ||||||||||||||||||||||||||||||||
Start Date ICMJE | May 2006 | ||||||||||||||||||||||||||||||||
Primary Completion Date | December 2007 (final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||||||||||||||||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||||||||||||||
Change History | Complete list of historical versions of study NCT00689000 on ClinicalTrials.gov Archive Site | ||||||||||||||||||||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||||||||||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||||||||||||||
Current Other Outcome Measures ICMJE | |||||||||||||||||||||||||||||||||
Original Other Outcome Measures ICMJE | |||||||||||||||||||||||||||||||||
Descriptive Information | |||||||||||||||||||||||||||||||||
Brief Title ICMJE | Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | ||||||||||||||||||||||||||||||||
Official Title ICMJE | A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma | ||||||||||||||||||||||||||||||||
Brief Summary | This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases:
|
||||||||||||||||||||||||||||||||
Detailed Description | This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: Phase I: an open-label, dose-escalating phase of the study to explore the safety, tolerability, and pharmacokinetics (PK) of CHR-2797. Cohorts of 3-6 patients each will be treated with escalating, once daily, oral doses of CHR-2797 for 84 days (12 weeks), of which the first 28 days constitute the dose finding/ DLT phase. The starting dose will be 60 mg once daily. Doses will be increased in a stepwise fashion by around 40 percent per step until the MTD is reached. The proportion of patients with Multiple Myeloma will be limited to one third: one per cohort of 3 or 2 per cohort of 6. It is anticipated that 24-30 patients will be enrolled in the phase I portion of the trial. A decision will be made with regard to the disease indication to be tested in phase II (either AML/MDS or MM or both), after completion of phase I, or following definition of MTD. Phase II: the recommended dose as determined in phase I, will be administered for 84 days to a maximum of 40 patients. The primary objective is to determine whether CHR-2797 has sufficient biological activity against the disease(s) under study. A multinomial stopping rule has been included in the design that incorporates objective responses and early progression into a decision to stop or continue this phase I/II trial. An interim assessment will be performed after 15 patients have received the maximum acceptable dose (MAD) dose of CHR-2797 with clearly defined early stopping rules. There will be a clinical conference at the end of every cohort in the phase I portion of the study, between phase I and II and after the first 15 patients have completed therapy in phase II. |
||||||||||||||||||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||||||||||||||||||
Study Phase | Phase 1 Phase 2 |
||||||||||||||||||||||||||||||||
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
||||||||||||||||||||||||||||||||
Condition ICMJE |
|
||||||||||||||||||||||||||||||||
Intervention ICMJE | Drug: CHR-2797 (tosedostat): Aminopeptidase inhibitor
Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study Other Names:
|
||||||||||||||||||||||||||||||||
Study Arm (s) | Experimental: CHR-2797 (tosedostat)
oral, once daily administration of CHR-2797 to determine safety & anti-disease activity.
Intervention: Drug: CHR-2797 (tosedostat): Aminopeptidase inhibitor |
||||||||||||||||||||||||||||||||
Publications * | Löwenberg B, Morgan G, Ossenkoppele GJ, Burnett AK, Zachée P, Dührsen U, Dierickx D, Müller-Tidow C, Sonneveld P, Krug U, Bone E, Flores N, Richardson AF, Hooftman L, Jenkins C, Zweegman S, Davies F. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2010 Oct 1;28(28):4333-8. Epub 2010 Aug 23. | ||||||||||||||||||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||||||||||||||||
Recruitment Information | |||||||||||||||||||||||||||||||||
Recruitment Status ICMJE | Completed | ||||||||||||||||||||||||||||||||
Enrollment ICMJE | 57 | ||||||||||||||||||||||||||||||||
Completion Date | December 2007 | ||||||||||||||||||||||||||||||||
Primary Completion Date | December 2007 (final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||||||||||||||||||
Gender | Both | ||||||||||||||||||||||||||||||||
Ages | 18 Years and older | ||||||||||||||||||||||||||||||||
Accepts Healthy Volunteers | No | ||||||||||||||||||||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||||||||||||||||||
Location Countries ICMJE | United Kingdom | ||||||||||||||||||||||||||||||||
Administrative Information | |||||||||||||||||||||||||||||||||
NCT Number ICMJE | NCT00689000 | ||||||||||||||||||||||||||||||||
Other Study ID Numbers ICMJE | CHR-2797-002 | ||||||||||||||||||||||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||||||||||||||||||||||
Responsible Party | Dr Leon Hooftman, Chief Medical Officer, Chroma Therapeutics | ||||||||||||||||||||||||||||||||
Study Sponsor ICMJE | Chroma Therapeutics | ||||||||||||||||||||||||||||||||
Collaborators ICMJE | |||||||||||||||||||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||||||||||||||||||
Information Provided By | Chroma Therapeutics | ||||||||||||||||||||||||||||||||
Verification Date | October 2010 | ||||||||||||||||||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |